Screener
Aclaris Therapeutics ACRS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses | 5,959 | 8,791 |
| Deferred income | 3,976 | 3,943 |
| Other current liabilities | 2,790 | 2,753 |
| Total current liabilities | 28,241 | 28,645 |
| Other liabilities | 1,262 | 1,565 |
| Deferred income, net of current portion | 14,309 | 16,168 |
| Contingent consideration | 11,300 | 11,000 |
| Total liabilities | 55,112 | 57,378 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's total current liabilities?
- Aclaris Therapeutics (ACRS) reported total current liabilities of $28.24M in Q2 2026.
- How has Aclaris Therapeutics's total current liabilities changed year-over-year?
- Aclaris Therapeutics's total current liabilities increased by 5.2% year-over-year, from $26.84M to $28.24M.
- What is the long-term trend for Aclaris Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's total current liabilities has grown at a 14.0% compound annual growth rate (CAGR), from $14.87M to $28.65M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Aclaris Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude